

VIRGINIA HEMOPHILIA FOUNDATION

AUDITED FINANCIAL STATEMENTS
YEARS ENDED
JUNE 30, 2024 AND JUNE 30, 2023

VIRGINIA HEMOPHILIA FOUNDATION

CONTENTS

	Page
Independent Auditor's Report.....	1-2
Statement of Financial Position – as of June 30, 2024 and June 30, 2023	3
Statement of Activities - for the Year Ending June 30, 2024.....	4
Statement of Activities - for the Year Ending June 30, 2023.....	5
Statement of Functional Expenses - for the Year Ending June 30, 2024.....	6
Statement of Functional Expenses - for the Year Ending June 30, 2023.....	7
Statement of Cash Flows - for the Year Ending June 30, 2024 and June 30, 2023	8
Notes to Financial Statements.....	9-13



HOSTETLER STOTT, CPA

www.hostetlerstott.com

One Morton Drive, Suite 410,
PO Box 4487, Charlottesville, VA 22905

PHONE: 434.979.5514 FAX: 434.979.9450

INDEPENDENT AUDITOR'S REPORT

September 20, 2024

Board of Directors
Virginia Hemophilia Foundation
Richmond, VA

Opinion

We have audited the accompanying financial statements of Virginia Hemophilia Foundation (a Virginia nonprofit corporation), which comprise the statement of financial position as of June 30, 2024 and June 30, 2023 and the related statements of activities, functional expenses and cash flows for the years then ended, and the related notes to the financial statements.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Virginia Hemophilia Foundation, as of June 30, 2024 and June 30, 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with the accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America. Our responsibilities under those standards are further described in the Auditors Responsibilities for the Audit of the Financial Statement section of our report. We are required to be independent of Virginia Hemophilia Foundation and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibility of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Virginia Hemophilia Foundation's ability to continue as a going concern within one year after the date that the financial statements are available to be issued.


Auditor's Responsibility

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than one from resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risk of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Virginia Hemophilia Foundation's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Virginia Hemophilia Foundation's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control related matters that we identified during the audit.



Hostetler Stott CPA
Charlottesville, VA

VIRGINIA HEMOPHILIA FOUNDATION

Statement of Activities

For the Year Ending June 30, 2024

	Without Donor Restrictions	With Donor Restrictions	Total
Support, revenue and losses:			
Contributions and grants	\$ 481,554	\$ 16,074	\$ 497,628
Advertising income	14,450	-	14,450
Registrations	3,227	-	3,227
Investment income	68,891	-	68,891
Realized & unrealized gain/(loss), net of related expenses	69,007	-	69,007
Gain (loss) on disposal of assets	(285)	-	(285)
Total support, revenue and losses	636,844	16,074	652,918
Reclassifications:			
Net assets released from restrictions	26,661	(26,661)	-
Total reclassifications	26,661	(26,661)	-
Total revenue and reclassifications	663,505	(10,587)	652,918
Expenses			
Program services	416,260	-	416,260
Management and general	23,770	-	23,770
Fundraising	19,092	-	19,092
Total expenses	459,122	-	459,122
Change in net assets before income taxes	204,383	(10,587)	193,796
Income taxes	-	-	-
Change in net assets	204,383	(10,587)	193,796
Net assets at beginning of year	1,690,349	19,159	1,709,508
Net assets at end of year	<u>\$1,894,732</u>	<u>\$ 8,572</u>	<u>\$1,903,304</u>

VIRGINIA HEMOPHILIA FOUNDATION

Statement of Activities For the Year Ending June 30, 2023

	Without Donor Restrictions	With Donor Restrictions	Total
Support, revenue and losses:			
Contributions and grants	\$ 388,556	\$ 33,500	\$ 422,056
In-kind contributions	170	-	170
Fundraising and special events	38,719	-	38,719
Less: direct donor benefits	(2,471)	-	(2,471)
Advertising income	5,950	-	5,950
Registrations	1,150	-	1,150
Memorial income	100	-	100
Investment income	46,808	-	46,808
Realized & unrealized gain/(loss), net of related expenses	7,846	-	7,846
Total support, revenue and losses	486,828	33,500	520,328
Reclassifications:			
Net assets released from restrictions	44,721	(44,721)	-
Total reclassifications	44,721	(44,721)	-
Total revenue and reclassifications	531,549	(11,221)	520,328
Expenses			
Program services	363,938	-	363,938
Management and general	21,098	-	21,098
Fundraising	18,421	-	18,421
Total expenses	403,457	-	403,457
Change in net assets before income taxes	128,092	(11,221)	116,871
Income taxes	-	-	-
Change in net assets	128,092	(11,221)	116,871
Net assets at beginning of year	1,562,257	30,380	1,592,637
Net assets at end of year	\$ 1,690,349	\$ 19,159	\$ 1,709,508

VIRGINIA HEMOPHILIA FOUNDATION

Statement of Functional Expenses

For the Year Ending June 30, 2024

	Program Services	Supporting Services		Total
		Management & General	Fundraising	
Salaries	\$ 178,703	\$ 7,280	\$ 12,117	\$ 198,100
Payroll tax	13,032	532	884	14,448
Employee benefits	24,563	979	1,650	27,192
Total compensation	216,298	8,791	14,651	239,740
Program support	70,478	-	-	70,478
Professional fees	49,760	9,333	2,888	61,981
Scholarships	32,212	-	-	32,212
Meeting expense	16,475	641	-	17,116
Travel & training	9,587	55	-	9,642
Insurance	6,094	248	413	6,755
Office expense	4,242	1,089	791	6,122
Telephone	4,598	-	-	4,598
Family assistance	4,057	-	-	4,057
Rent	-	2,919	-	2,919
Donations	1,400	-	-	1,400
Dues	336	440	300	1,076
Depreciation	723	29	49	801
Licenses	-	225	-	225
Total expenses	\$ 416,260	\$ 23,770	\$ 19,092	\$ 459,122

VIRGINIA HEMOPHILIA FOUNDATION

Statement of Functional Expenses

For the Year Ending June 30, 2023

	Program Services	Supporting Services		Total
		Management & General	Fundraising	
Salaries	\$ 161,942	\$ 6,615	\$ 10,994	\$ 179,551
Payroll tax	11,716	478	795	12,989
Employee benefits	25,126	1,042	1,528	27,696
Total compensation	198,784	8,135	13,317	220,236
Program support	61,665	-	-	61,665
Professional fees	42,978	8,680	2,423	54,081
Meeting expense	25,904	37	-	25,941
Travel & training	9,157	14	76	9,247
Office expense	3,802	1,122	1,875	6,799
Insurance	5,709	234	383	6,326
Scholarships	4,600	-	-	4,600
Telephone	4,466	-	-	4,466
Family assistance	4,058	-	-	4,058
Rent	-	2,372	-	2,372
Dues	811	240	300	1,351
Donations	1,300	-	-	1,300
Depreciation	704	29	47	780
Licenses	-	235	-	235
Total expenses before direct donor benefits	363,938	21,098	18,421	403,457
Direct donor benefits	-	-	2,471	2,471
Total expenses including direct donor benefits	\$ 363,938	\$ 21,098	\$ 20,892	\$ 405,928

VIRGINIA HEMOPHILIA FOUNDATION

Statement of Cash Flows

For the Years Ending June 30, 2024 and June 30, 2023

	2024	2023
Cash flows from operating activities:		
Change in net assets	\$ 193,796	\$ 116,871
Depreciation	800	780
Loss on disposal of assets	285	-
Realized & unrealized (gain) or loss on investments	(69,007)	(7,846)
(Increase)/decrease in pledges and grants receivable	1,426	5,750
(Increase)/decrease in prepaid expenses	88	(29,979)
Increase/(decrease) in credit cards	(3,909)	(2,059)
Increase/(decrease) in accrued payroll and taxes	921	3,458
Increase/(decrease) in accrued expenses	(100)	(172)
Increase/(decrease) in deferred advertising revenue	5,950	1,700
Increase/(decrease) in conditional contributions	(46,000)	(17,000)
Net cash provided by operating activities:	84,250	71,503
 Cash flows from investing activities:		
Purchase of investments	(68,891)	(86,808)
Proceeds from sale of investments	30,000	-
Purchase of equipment	-	(753)
Proceeds from sale of equipment	210	-
Net cash used by investing activities:	(38,681)	(87,561)
 Net increase/(decrease) in cash and cash equivalents	45,569	(16,058)
 Cash and cash equivalents at beginning of year	122,518	138,576
 Cash and cash equivalents at end of year	\$ 168,087	\$ 122,518
 Supplemental data:		
Interest paid	\$ -	\$ -
Income taxes paid	\$ -	\$ -

VIRGINIA HEMOPHILIA FOUNDATION

Notes to Financial Statements

June 30, 2024

Organization and Nature of Activities

The Virginia Hemophilia Foundation (the Organization) is a tax-exempt, nonprofit Virginia corporation (IRS Code Section 501(c)(3)) which provides services and support in Virginia to individuals impacted by inherited bleeding disorders, and also provides education concerning inherited bleeding disorders to the general public. Revenue sources are corporate and individual contributions and grants, fundraising events, sponsorships, registrations and advertising revenue. There is no charge for client services.

Summary of Significant Accounting Policies

Financial Statement Presentation

The Organization reports its financial statements using the accrual basis of accounting in accordance with generally accepted accounting principles.

Contributions and Grants

All contributions are recognized when promised by or received from the donor and are considered to be available for unrestricted use unless specifically restricted by the donor. Contributions are reported as without or with donor restrictions based on the existence in nature of any donor restrictions. Pledges and grants receivable at June 30, 2024 and June 30, 2023 were estimated to be collectible within one year. No bad debt expense was recognized for either fiscal year.

Conditional Contributions

During the fiscal year ended June 30, 2024 and 2023, the Organization received contributions in the form of sponsorships for events planned for the following fiscal year. At June 30, 2023, management considered \$47,500 conditional contributions due to the nature of the events and the possibility that they could be cancelled. At June 30, 2024, management considered \$1,500 conditional contributions due to the possibility that the sponsor would withdraw sponsorship for a future event. Conditional contributions are reported in the liabilities section of the Statement of Financial Position.

Advertising Income

Income from advertising is recognized when the advertisement is published. At June 30, 2024, \$9,350 of payments from advertising customers were not yet recognized since the advertisements had not yet been published. At June 30, 2023, \$3,400 of payments from advertising customers were not yet recognized since the advertisements had not yet been published. These amounts are reported as deferred advertising revenue in the liabilities sections of the Statement of Financial Position.

Cash and Cash Equivalents

For the purpose of the Statement of Cash Flows, the Organization considers all highly liquid investments with original maturities of three months or less to be cash equivalents. However, cash held in the investment account is included in the investments balance on the accompanying Statement of Financial Position.

VIRGINIA HEMOPHILIA FOUNDATION

Notes to Financial Statements

June 30, 2024

Investments

Investments consisted of cash, money markets, corporate bonds, and equities. The Organization estimates that the fair market values at June 30, 2024 and at June 30, 2023 do not differ materially from the carrying value recorded in the accompanying Statement of Financial Position.

Fair Values of Financial Instruments

The Financial Accounting Standards Board Codification of Accounting Standards Topic 820 established a framework for measuring fair value under accounting principles generally accepted in the United States of America. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value.

The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described below:

Level 1 – Quoted prices in active markets for identical assets the Organization has the ability to access at the measurement date. These types of quoted prices would include publicly traded securities.

Level 2 – Pricing inputs (other than quoted prices included in Level 1) that are observable for the asset, either directly or indirectly. Observable inputs are those that reflect the assumptions market participants would use in pricing the asset developed based on market date obtained from sources independent of the Organization. These types of sources would include quoted prices for similar assets, models or other valuation methodologies.

Level 3 – Pricing inputs that are unobservable for the asset. Unobservable inputs are those that reflect their own assumptions about the assumptions that market participants would use in pricing the asset developed based on the best information available. These types of sources would include investment manager pricing for private equities.

The carrying amounts for current assets and liabilities reported in the Statement of Financial Position approximate the fair market values.

The following table sets forth, by level, within the fair value hierarchy, amounts recorded in the Organization's financial statements at fair value as of June 30, 2024:

	<u>Fair Value</u>	<u>Level 1</u>	<u>Level 2</u>
Checking and savings	\$ 168,087	\$ 168,087	\$ -
Investment portfolio:			
Cash	238,004	238,004	-
Money market	338,019	338,019	-
Corporate bonds	718,655	-	718,655
Equities	415,195	415,195	-
Accrued Interest	7,129	7,129	-
Total	<u>\$ 1,885,089</u>	<u>\$ 1,166,434</u>	<u>\$ 718,655</u>

VIRGINIA HEMOPHILIA FOUNDATION

Notes to Financial Statements

June 30, 2024

Fair Values of Financial Instruments (Continued)

The following table sets forth, by level, within the fair value hierarchy, amounts recorded in the Organization's financial statements at fair value as of June 30, 2023:

	<u>Fair Value</u>	<u>Level 1</u>	<u>Level 2</u>
Checking and savings	\$ 122,518	\$ 122,518	\$ -
Investment portfolio:			
Cash	255,446	255,446	-
Money market	703,131	703,131	-
Corporate bonds	476,072	-	476,072
Equities	170,515	170,515	-
Accrued Interest	3,940	3,940	
Total	<u>\$ 1,731,622</u>	<u>\$ 1,255,550</u>	<u>\$ 476,072</u>

Investment expenses for the years ended June 30, 2024 and 2023 were \$3,792 and \$3,283 respectively. In the Statement of Activities, investment expenses have been netted against realized & unrealized gains.

Credit Risk

The Organization's financial instruments that are exposed to concentrations of credit risk consist primarily of cash and investments. At times, the Organization may have cash at a financial institution in excess of the federally insured limit of \$250,000. Investments are not federally insured but instead are insured by the Securities Investor Protection Corporation. The Organization places its cash with financial institutions whose credit ratings are monitored by management to minimize concentration of credit risk. As of June 30, 2024 and 2023, cash balances did not exceed FDIC limits.

Prepaid Expenses

Prepaid expenses at the end of the fiscal years are comprised of the following:

	<u>6/30/2024</u>	<u>6/30/2023</u>
Event deposits	\$ 30,605	\$ 17,820
National conference deposits	559	10,449
Health insurance	4,861	5,417
Other insurance	2,133	2,506
Software subscriptions	394	2,449
Other expenses	43	42
Total	<u>\$ 38,595</u>	<u>\$ 38,683</u>

VIRGINIA HEMOPHILIA FOUNDATION

Notes to Financial Statements

June 30, 2024

Property and Equipment

Acquisition of property and equipment are recorded at cost. Improvements and replacements of property and equipment with an original cost of \$500 or more are capitalized. Maintenance and repairs that do not improve or extend the lives of property and equipment are charged to expense as incurred. When assets are sold or retired, their cost and related accumulated depreciation are removed from the accounts and any gain or loss is reported in the Statement of Activities.

Depreciation and amortization are provided over the estimated useful life of each class life of depreciable assets and is computed using the straight-line method, as follows:

Assets	6/30/2024 Balance	6/30/2023 Balance	Estimated Life
Equipment	\$ 3,179	\$ 7,256	5 -7 years
Accumulated depreciation	(1,708)	(4,491)	
Net Property & equipment	<u>\$ 1,471</u>	<u>\$ 2,765</u>	

Liquidity and Availability to Meet Cash Needs

The following represents the Organization's financial assets as of the June 30, 2024 and 2023, reduced by amounts not available for general use because of contractual or donor-imposed restrictions within one year after that date:

Financial assets	6/30/2024	6/30/2023
Cash and cash equivalents	\$ 168,087	\$ 122,518
Investments	1,717,002	1,609,104
Net financial assets	1,885,089	1,731,622
Less: donor restricted cash	(4,998)	(14,159)
Available to meet general expenditures	<u>\$ 1,880,091</u>	<u>\$ 1,717,463</u>

Net Assets Released from Donor Restrictions

The Organization's net assets released from restrictions result from satisfaction of program restrictions and from the receipt of pledges recognized in the prior year.

Use of Estimates

The preparation of financial statements in accordance with accounting principles generally accepted in the United State of America requires management to make estimates and assumptions that affect certain reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates and may impact future periods.

VIRGINIA HEMOPHILIA FOUNDATION

Notes to Financial Statements

June 30, 2024

Income Taxes

As defined in Section 501(c)(3) of the Internal Revenue Code, the Organization is exempt from federal and state income taxes on its exempt purpose income. For the fiscal years ended June 30, 2024 and 2023, the Organization incurred no federal or state tax expense due to unrelated business income.

Uncertain Tax Positions

The Organization believes that it has appropriate support for any tax positions taken, and as such, does not have any uncertain tax positions that are material to the financial statements. The federal income tax returns of the Organization for fiscal year 2021 and forward are subject to examination by the Internal Revenue Service.

Donated Services

Many of the Organization's functions are carried out with the assistance of volunteers. No amounts have been recognized in the accompanying Statement of Activities because the criteria for recognition of such volunteer efforts under FASB Codification 720 "Accounting for Contributions Received and Contributions Made" have not been satisfied.

Net Assets with Donor Restrictions

Net assets with donor restrictions at June 30, 2024 and 2023 are held for the following purposes:

	<u>6/30/2024</u>	<u>6/30/2023</u>
Advocacy	\$ 1,407	\$ 8,659
Pledges & grants receivable	3,574	5,000
Other purposes	3,591	5,500
Total	<u>\$ 8,572</u>	<u>\$ 19,159</u>

Functional Allocation of Expense

The costs of providing the various programs and activities have been summarized on a functional basis in the Statement of Activities. Accordingly, certain costs have been allocated among the programs and supporting services benefited. Payroll costs and other payroll related expenses, as well as rent, professional fees, insurance, and depreciation expenses, are allocated based on management's estimated percentage of time spent by each employee in each program. Other expenses have been directly assigned to their associated function.

Subsequent Events

The Organization has evaluated events and transactions for potential recognition or disclosure in the financial statements through September 20, 2024, the date the financial statements were available to be issued. No subsequent events have been recognized or disclosed.